ICU sedation, delirium & recovery
Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update
Study context
- Population
- Adult patients with refractory or relapsed high-grade B cell malignancies treated with CAR-T cells
Methodological detailsshort pragmatic review, Six CAR-T cell products currently available for adults
- Short pragmatic review
- Six CAR-T cell products currently available for adults
Main finding
As reported in the abstract
- Synthesis for intensivists of CAR-T cell therapy: CAR-T cell-induced toxicities, ICU management of complications per international recommendations, outcomes and future issues
Safety
CAR-T cell toxicities
- Associated with severe life-threatening toxicities and side effects that may require ICU admission
Original publication
Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update. Crit Care. Published 5 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →